Uchegbu I - Search Results

1

Exploring uptake mechanisms of oral nanomedicines using multimodal nonlinear optical microscopy.

Garrett NL, Lalatsa A, Uchegbu I, Schätzlein A, Moger J. Garrett NL, et al. Among authors: uchegbu i. J Biophotonics. 2012 May;5(5-6):458-68. doi: 10.1002/jbio.201200006. Epub 2012 Mar 5. J Biophotonics. 2012. PMID: 22389316

2

Delivery of peptides to the blood and brain after oral uptake of quaternary ammonium palmitoyl glycol chitosan nanoparticles.

Lalatsa A, Garrett NL, Ferrarelli T, Moger J, Schätzlein AG, Uchegbu IF. Lalatsa A, et al. Among authors: uchegbu if. Mol Pharm. 2012 Jun 4;9(6):1764-74. doi: 10.1021/mp300068j. Epub 2012 May 21. Mol Pharm. 2012. PMID: 22571402

3

A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine(5)-enkephalin, to the brain.

Lalatsa A, Lee V, Malkinson JP, Zloh M, Schätzlein AG, Uchegbu IF. Lalatsa A, et al. Mol Pharm. 2012 Jun 4;9(6):1665-80. doi: 10.1021/mp300009u. Epub 2012 May 18. Mol Pharm. 2012. PMID: 22574705

4

Nanomedicines and nanodiagnostics come of age.

Uchegbu IF, Siew A. Uchegbu IF, et al. J Pharm Sci. 2013 Feb;102(2):305-10. doi: 10.1002/jps.23377. Epub 2012 Nov 22. J Pharm Sci. 2013. PMID: 23175462 Review.

5

Chitosan amphiphile coating of peptide nanofibres reduces liver uptake and delivers the peptide to the brain on intravenous administration.

Lalatsa A, Schätzlein AG, Garrett NL, Moger J, Briggs M, Godfrey L, Iannitelli A, Freeman J, Uchegbu IF. Lalatsa A, et al. Among authors: uchegbu if. J Control Release. 2015 Jan 10;197:87-96. doi: 10.1016/j.jconrel.2014.10.028. Epub 2014 Nov 5. J Control Release. 2015. PMID: 25449808

6

Lomustine Nanoparticles Enable Both Bone Marrow Sparing and High Brain Drug Levels - A Strategy for Brain Cancer Treatments.

Fisusi FA, Siew A, Chooi KW, Okubanjo O, Garrett N, Lalatsa K, Serrano D, Summers I, Moger J, Stapleton P, Satchi-Fainaro R, Schätzlein AG, Uchegbu IF. Fisusi FA, et al. Among authors: uchegbu if. Pharm Res. 2016 May;33(5):1289-303. doi: 10.1007/s11095-016-1872-x. Epub 2016 Feb 22. Pharm Res. 2016. PMID: 26903051 Free PMC article.

7

A Self-Assembling Lipidic Peptide and Selective Partial V2 Receptor Agonist Inhibits Urine Production.

Patel S, Volpe AB, Awwad S, Schätzlein AG, Haider S, Liu B, Uchegbu IF. Patel S, et al. Sci Rep. 2020 Apr 29;10(1):7269. doi: 10.1038/s41598-020-64070-9. Sci Rep. 2020. PMID: 32350300 Free PMC article.

8

Down-regulation of GP130 signaling sensitizes bladder cancer to cisplatin by impairing Ku70 DNA repair signaling and promoting apoptosis.

He S, Li G, Schätzlein AG, Humphrey PA, Weiss RM, Uchegbu IF, Martin DT. He S, et al. Cell Signal. 2021 May;81:109931. doi: 10.1016/j.cellsig.2021.109931. Epub 2021 Jan 30. Cell Signal. 2021. PMID: 33529758

9

A polymeric aqueous tacrolimus formulation for topical ocular delivery.

Badr MY, Abdulrahman NS, Schatzlein AG, Uchegbu IF. Badr MY, et al. Int J Pharm. 2021 Apr 15;599:120364. doi: 10.1016/j.ijpharm.2021.120364. Epub 2021 Feb 8. Int J Pharm. 2021. PMID: 33571621

10

Achieving highly efficient gene transfer to the bladder by increasing the molecular weight of polymer-based nanoparticles.

Li G, He S, Schätzlein AG, Weiss RM, Martin DT, Uchegbu IF. Li G, et al. J Control Release. 2021 Apr 10;332:210-224. doi: 10.1016/j.jconrel.2021.02.007. Epub 2021 Feb 17. J Control Release. 2021. PMID: 33607176

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results